US008691232B2

(12) **United States Patent**
Derynck et al.

(10) **Patent No.: US 8,691,232 B2**
(45) **Date of Patent: *Apr. 8, 2014**

(54) **EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS**

(75) Inventors: **Mika K. Derynck**, San Mateo, CA (US); **Stephen M. Kelsey**, Montara, CA (US)

(73) Assignee: **Genentech, Inc.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/010,985**

(22) Filed: **Jan. 21, 2011**

(65) **Prior Publication Data**

US 2011/0165157 A1 Jul. 7, 2011

Related U.S. Application Data

(63) Continuation of application No. 12/271,564, filed on Nov. 14, 2008, now abandoned, which is a continuation of application No. 11/359,185, filed on Feb. 21, 2006, now abandoned.

(60) Provisional application No. 60/655,277, filed on Feb. 23, 2005.

(51) **Int. Cl.**
A61K 39/395 (2006.01)

(52) **U.S. Cl.**
USPC **424/155.1**; 424/138.1; 424/143.1

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,935,341	A	6/1990	Bargmann et al.
4,968,603	A	11/1990	Slamon et al.
5,183,884	A	2/1993	Kraus et al.
5,288,477	A	2/1994	Bacus
5,401,638	A	3/1995	Carney et al.
5,480,968	A	1/1996	Kraus et al.
5,514,554	A	5/1996	Bacus
5,571,894	A	11/1996	Wels et al.
5,587,458	A	12/1996	King et al.
5,604,107	A	2/1997	Carney et al.
5,641,869	A	6/1997	Vandlen et al.
5,648,237	A	7/1997	Carter
5,677,171	A	10/1997	Hudziak et al.
5,705,157	A	1/1998	Greene
5,720,937	A	2/1998	Hudziak et al.
5,720,954	A	2/1998	Hudziak et al.
5,725,856	A	3/1998	Hudziak et al.
5,747,261	A	5/1998	King et al.
5,770,195	A	6/1998	Hudziak et al.
5,772,997	A	6/1998	Hudziak et al.
5,783,186	A	7/1998	Arakawa et al.
5,783,404	A	7/1998	Koski
5,804,396	A	9/1998	Plowman
5,821,337	A	10/1998	Carter et al.
5,824,311	A	10/1998	Greene et al.
5,837,243	A	11/1998	Deo et al.
5,846,749	A	12/1998	Slamon et al.
5,856,089	A	1/1999	Wang et al.
5,877,305	A	3/1999	Huston et al.
5,910,486	A	6/1999	Curiel et al.
5,922,845	A	7/1999	Deo et al.
5,925,519	A	7/1999	Jensen et al.
5,939,531	A	8/1999	Wels et al.
5,977,322	A	11/1999	Marks et al.
5,985,553	A	11/1999	King et al.
5,994,071	A	11/1999	Ross et al.
6,015,567	A	1/2000	Hudziak et al.
6,028,059	A	2/2000	Curiel et al.
6,054,297	A	4/2000	Carter et al.
6,123,939	A	9/2000	Shawver et al.
6,127,526	A	10/2000	Blank
6,165,464	A	12/2000	Hudziak et al.
6,214,388	B1	4/2001	Benz et al.
6,267,958	B1	7/2001	Andya et al.
6,270,765	B1	8/2001	Deo et al.
6,333,169	B1	12/2001	Hudziak et al.
6,333,348	B1	12/2001	Vogel et al.
6,333,398	B1	12/2001	Blank
6,339,142	B1	1/2002	Basey et al.
6,358,682	B1	3/2002	Jaffee et al.
6,387,371	B1	5/2002	Hudziak et al.
6,395,272	B1	5/2002	Deo et al.
6,399,063	B1	6/2002	Hudziak et al.
6,403,630	B1	6/2002	Dannenberg et al.
6,407,213	B1	6/2002	Carter et al.
6,417,335	B1	7/2002	Basey et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 599 274 A1	11/1993
EP	0 616 812 B1	9/1994

(Continued)

OTHER PUBLICATIONS

Agus et al (J Clinical Oncology, 2005, 23:1534-2543, published online Feb. 7, 2005).*

Genentech Press Release, Jun. 1, 2003.*

Aasland et al., "Expression of Oncogenes in Thyroid Tumours: Coexpression of c-erbB2/neu and c-erbB" *British Journal of Cancer* 57(4):358-363 (Apr. 1988).

(Continued)

Primary Examiner — Laura B Goddard

(74) *Attorney, Agent, or Firm* — Wendy M. Lee

(57) **ABSTRACT**

The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.

34 Claims, 18 Drawing Sheets